Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2006/129679
Kind Code:
A1
Abstract:
The invention is directed to a CXCR3 antagonist comprising a compound represented by the general formula (I) (wherein all the symbols have the same meaning as defined in the description), a salt thereof, a quaternary ammonium salt thereof, an N-oxide form thereof or a solvate thereof, or a prodrug thereof. This antagonist is useful as a preventive, therapeutic and/or progression-suppressing agent for a CXCR3-mediated disease such as an immune or allergic disease [e.g., an atopic disease, an autoimmune disease (e.g., multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, glomerulonephritis, Sjogren's syndrome or the like), systemic inflammatory response syndrome (SIRS), rejection response to transplanted organ, tissue and/or cell or the like], a gastrointestinal disease [e.g., an inflammatory bowel disease or the like], or a respiratory disease [e.g., asthma, a chronic obstructive lung disease or the like].

Inventors:
HABASHITA HIROMU (JP)
SHIBAYAMA SHIRO (JP)
Application Number:
PCT/JP2006/310814
Publication Date:
December 07, 2006
Filing Date:
May 30, 2006
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ONO PHARMACEUTICAL CO (JP)
HABASHITA HIROMU (JP)
SHIBAYAMA SHIRO (JP)
International Classes:
A61K31/499; A61K31/527; A61P1/04; A61P1/16; A61P3/10; A61P9/10; A61P11/00; A61P11/06; A61P13/12; A61P17/00; A61P17/06; A61P19/02; A61P25/00; A61P27/02; A61P27/16; A61P29/00; A61P31/18; A61P35/00; A61P37/06; A61P37/08; A61P43/00; C07D221/20; C07D471/10
Domestic Patent References:
WO2005035534A12005-04-21
WO2004092169A12004-10-28
WO2003028732A12003-04-10
WO2006004925A12006-01-12
WO2002085862A12002-10-31
WO2002083143A12002-10-24
WO2001016114A22001-03-08
WO2003070242A12003-08-28
WO2004094381A12004-11-04
WO2005003127A12005-01-13
WO1997011940A11997-04-03
WO1998025605A11998-06-18
WO2002074770A12002-09-26
WO2004092169A12004-10-28
WO2003028732A12003-04-10
WO2001040227A12001-06-07
WO2004092169A12004-10-28
WO1999007351A21999-02-18
WO1999040913A11999-08-19
WO2000046195A12000-08-10
WO2000046196A12000-08-10
WO2000046197A12000-08-10
WO2000046198A12000-08-10
WO2000046199A22000-08-10
WO2000069432A12000-11-23
WO2000069815A12000-11-23
WO1999055324A11999-11-04
WO1999055330A11999-11-04
WO2000004003A12000-01-27
WO2000027800A12000-05-18
WO2000027835A12000-05-18
WO2000027843A12000-05-18
WO2000029377A12000-05-25
WO2000031032A12000-06-02
WO2000031033A12000-06-02
WO2000034278A12000-06-15
WO2000035449A12000-06-22
WO2000035451A12000-06-22
WO2000035452A12000-06-22
WO2000035453A12000-06-22
WO2000035454A12000-06-22
WO2000035876A12000-06-22
WO2000035877A12000-06-22
WO2000041685A12000-07-20
WO2000051607A12000-09-08
WO2000051608A12000-09-08
WO2000051609A12000-09-08
WO2000051610A12000-09-08
WO2000053172A12000-09-14
WO2000053600A12000-09-14
WO2000058305A12000-10-05
WO2000059497A12000-10-12
WO2000059498A12000-10-12
WO2000059502A12000-10-12
WO2000059503A12000-10-12
WO2000062814A22000-10-26
WO2000073327A12000-12-07
WO2001009088A12001-02-08
WO1999017773A11999-04-15
WO1999032100A21999-07-01
WO2000006085A22000-02-10
WO2000006146A12000-02-10
WO2000010965A22000-03-02
WO2000006153A12000-02-10
WO2000021916A12000-04-20
WO2000037455A12000-06-29
WO2000038680A12000-07-06
WO2000039125A12000-07-06
WO2000040239A12000-07-13
WO2000042045A22000-07-20
WO2000053175A12000-09-14
WO2000042852A12000-07-27
WO2000066551A12000-11-09
WO2000066558A12000-11-09
WO2000066559A12000-11-09
WO2000066141A22000-11-09
WO2000068203A12000-11-16
WO2000051608A12000-09-08
WO2000051610A12000-09-08
WO2000056729A12000-09-28
WO2000059502A12000-10-12
WO2000059503A12000-10-12
WO2000076933A22000-12-21
WO1999004794A11999-02-04
WO1999038514A11999-08-05
WO2002083143A12002-10-24
WO2002085862A12002-10-31
WO2003101970A12003-12-11
WO2004094381A12004-11-04
WO2005003127A12005-01-13
WO2000066112A12000-11-09
WO2004024697A12004-03-25
Foreign References:
US5962462A1999-10-05
DE19837386A11999-02-25
EP1013276A12000-06-28
JP2000309598A2000-11-07
US6469002B12002-10-22
Other References:
GAO P.: "The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Thl chemokine receptors CCR5 and CXCR3", J. LEUKOC. BIOL., vol. 73, no. 2, 2003, pages 273 - 280, XP002981402
MAHAD D.J.: "Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse", MULT. SCLER., vol. 9, no. 2, 2003, pages 189 - 198, XP008073370
HIROKAWA SHOTEN: "lyakuhin no Kaihatsu", BUNSHISEKKEI, vol. 7, 1990, pages 163 - 198
"The Merck Manual of Diagnosis and Therapy", MERCK & CO.
RICHARD C. LAROCK: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", 1999, JOHN WILEY & SONS INC
BIOORG. MED. CHEM. LETT., vol. 10, 2000, pages 1803
BIOORG. MED. CHEM. LETT., vol. 11, 2003, pages 2663
Attorney, Agent or Firm:
Iwatani, Ryo (Dojima 2-chome Kita-k, Osaka-shi Osaka03, JP)
Download PDF: